Atherosclerotic Cardiovascular Disease
Future of FH involves more screening, patient empowerment
ATLANTA — Although progress has been made in diagnosing and treating patients with familial hypercholesterolemia, more work is needed in these areas, according to a presentation at the FH Foundation’s FH Global Summit.
Familial hypercholesterolemia may be risk equivalent to ASCVD
Patients with familial hypercholesterolemia who were treated in U.S. specialty clinics had a harder time achieving LDL less than 100 mg/dL than those who had atherosclerotic CVD at the start of lipid-lowering therapy.
Part of the Healio Network
Triglycerides
Triglycerides are a form of lipid ester that contain glycerol and three fatty acids. There are many types of triglycerides, and they play an important role in metabolism.
Part of the Healio Network
Coronary Artery Calcium (CAC) Score Topic Review
The coronary artery calcium score enhances clinical risk stratification for patients at risk for atherosclerotic coronary disease.
Statins are Antibiotics…is THAT the Pleiotropic Effect?
A look at ezetimibe and the IMPROVE-IT trial
It is well known that HMG-CoA reductase inhibitors reduce LDL, a surrogate marker in atherosclerotic disease, as well as primary and secondary CHD events, the need for revascularization and ischemic stroke.
Part of the Healio Network
Aspirin Topic Review
Aspirin (acetylsalicylic acid) is a versatile drug from the salicylate class.
Part of the Healio Network
Atherosclerosis Topic Review
Atherosclerosis is a chronic, systemic, inflammatory and metabolic disease and pathologic process characterized by the accumulation of cholesterol and calcium plaque within the arterial wall. [Kobiyama K, et al. Circ Res. 2018;1a]
Part of the Healio Network
Acute Coronary Syndromes Review
An acute coronary syndrome occurs when atherosclerotic coronary plaque becomes unstable, leading to a series of events eventually resulting in partial or total thrombotic occlusion of a coronary artery.
Part of the Healio Network
Ezetimibe Topic Review
Ezetimibe is a nonstatin low-density lipoprotein cholesterol-lowering small molecule drug.